Sign In
Buy RLMD
$6.33
-0.0900 (-1.40%)
At Close: Jun 03, 2026
CORAL GABLES, Fla. , Oct. 6, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
LOS ANGELES, CA / ACCESSWIRE / October 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therape
LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Ther
Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate
03:02pm, Thursday, 21'st Sep 2023
Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
08:30am, Wednesday, 20'th Sep 2023
Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment Long-term dosin
Relmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim Readout
06:53pm, Friday, 01'st Sep 2023
Relmada Therapeutics has provided updates on its phase 3 program of esmethadone (REL-1017) as an adjunct in major depressive disorder. An interim analysis could result in an early stoppage, it isn't a
Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
07:30am, Thursday, 08'th Jun 2023
CORAL GABLES, Fla. , June 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference
07:30am, Friday, 02'nd Jun 2023
CORAL GABLES, Fla. , June 2, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting
07:30am, Wednesday, 24'th May 2023
CORAL GABLES, Fla. , May 24, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
Relmada Therapeutics, Inc. (RLMD) Q1 2023 Earnings Call Transcript
09:10pm, Friday, 12'th May 2023
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - Chief Executive Officer Cedric
Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023
07:30am, Monday, 08'th May 2023
CORAL GABLES, Fla. , May 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
Relmada Therapeutics, Inc. (RLMD) Q4 2022 Earnings Call Transcript
10:27pm, Thursday, 23'rd Mar 2023
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - CEO Maged Shenouda - CFO Ced
CORAL GABLES, Fla. , March 17, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc
Relmada Therapeutics shares decline 40% on Thursday
08:39am, Thursday, 08'th Dec 2022
Shares of Relmada Therapeutics Inc. RLMD, -0.95% tumbled about 40% in premarket trading on Thursday, the day after the company said its experimental depression drug did not meet the primary endpoint i
Relmada Therapeutics, Inc. (RLMD) Q3 2022 Earnings Call Transcript
08:33am, Saturday, 12'th Nov 2022
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Sergio Traversa - Chief Executive Officer
